Kyntra Bio, Inc.
- KYNB
- NASDAQ
- Biotechnology
- Hypoxia-Targeted Therapies
- Clinical-Stage Biotech
- Drug Discovery
$5.28
Today +8.87%Quote Oct 19, 2026, 08:00 PM UTC
−25.37%over the last month
Max drawdown −33.4%From 1-month high −27.5%3 months −27.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
34
Market value
$21.4M
Quote Oct 19
Analyst target
$28.00
+430.3% from here
Floor
$5.23
0.9% below price
Resistance
$5.67
7.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KYNBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free